Breast

Triple negative breast cancer (TNBC)

- Early stage TNBC
- Locally advanced/metastatic TNBC

Hormone Receptor Positive (HR+)

- Locally advanced/metastatic ER+ and/or PR+/HER2-
- Non HER2 positive with BRCA mutation
- PTEN or PIK3CB mutation (TNBC or ER+/HER2-)
- With residual cancer burden (TNBC or ER+ and/or PR+, HER2- BC)
- Expansion: Locally advanced/metastatic HER2-
- Bone metastatic breast cancer (TNBC or ER+ and/or PR+)
- HER2+ PIK3CA mutation, PTEN mutation or PTEN loss.

TNBC or HR+

- Locally advanced/metastatic ER+/HER2-
- With residual cancer burden (TNBC or ER+ and/or PR+, HER2- BC)
- Expansion: Locally advanced/metastatic HER2-
- Bone metastatic breast cancer (TNBC or ER+ and/or PR+)
- HER2+ PIK3CA mutation, PTEN mutation or PTEN loss.

HER2 Positive

- Locally advanced/metastatic ER+ and/or PR+/HER2-
- Non HER2 positive with BRCA mutation
- PTEN or PIK3CB mutation (TNBC or ER+/HER2-)
- With residual cancer burden (TNBC or ER+ and/or PR+, HER2- BC)
- Expansion: Locally advanced/metastatic HER2-
- Bone metastatic breast cancer (TNBC or ER+ and/or PR+)
- HER2+ PIK3CA mutation, PTEN mutation or PTEN loss.

**10013**: Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (TNBC)

**10146**: Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab in Patients with Metastatic Triple Negative Breast Cancer

**9881**: A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (4 cohorts: NSCLC, TNBC, PDAC, SCLC)

**10031**: A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (Currently in dose escalation)

**10387**: A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)

**10195**: A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination with Fulvestrant in Women with Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor

**10020**: A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab, MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer

**10131**: A Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Currently in dose escalation. Expansion cohorts include breast, prostate, and other solid tumors.)

**10291**: A Phase 1b Study of M6620 in Combination with Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

**9844**: A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or Without Ipilimumab in Advanced Solid Tumors

**10302**: Phase II Trial of Radium-223 in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer

**10296**: Phase Ib/II Trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive (HER2+) metastatic breast cancer (MBC) with PIK3CA mutation, PTEN mutation or PTEN loss

**10107**: A Randomized Phase I/II Study of HSP90 Inhibitor, AT13387 in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer

**10117**: A Phase 1 Study of Cediranib and Atezolizumab in Patients with HER2 Positive Breast Cancer

**10123**: A Phase 2 Study of Abemaciclib in Combination with Bevacizumab and Paclitaxel in ER+HER2- Metastatic Breast Cancer

**10129**: A Phase 1 Study of Olaparib in Combination with Bevacizumab and Paclitaxel in HER2 Positive Metastatic Breast Cancer

**10132**: A Phase 1 Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Currently in dose escalation. Expansion cohorts include breast, prostate, and other solid tumors.)

**10133**: A Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Currently in dose escalation. Expansion cohorts include breast, prostate, and other solid tumors.)

**10135**: A Phase II Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or Without Ipilimumab in Advanced Solid Tumors

**10297**: Phase Ib Study of HSP90 Inhibitor, AT13387 in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer

**10301**: Phase Ib Trial of Atezolizumab and Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer

**10306**: Phase II Trial of Binding Congeners of Triphenylethylene (TPE) and Paclitaxel in Patients with Bone Metastatic Breast Cancer

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: February 13, 2019